Loading...
NPI 1467890137 · Eugene, OR · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Nepenthe Laboratory Services LLC is a clinical medical laboratory provider located in Eugene, Oregon. This profile covers 5 Medicare and 12 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Nepenthe Laboratory Services LLC |
| Address | 1710 Willow Creek Circle, Ste #2 |
| City | Eugene |
| State | OR |
| ZIP | 97402 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | June 4, 2013 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $16.6M |
| Medicare | $421.4K |
NEPENTHE LABORATORY SERVICES LLC is operating primarily as a clinical drug-testing laboratory: its top Medicare and Medicaid revenue codes are dominated by definitive and presumptive drug testing codes (G0480, G0481, G0482, G0483 and 80307), indicating core services are high-volume toxicology confirmation and instrumented drug screening rather than general clinical chemistry or pathology panels. The presence of multiple G048x definitive test codes alongside 80307 suggests it performs both broad presumptive screens and follow-up definitive identification using methods like GC/MS or LC/MS.
Medicaid revenue materially outweighs Medicare revenue for this entity: total Medicaid revenue is $16.6M versus total Medicare revenue of $421.4K, indicating the provider operates at scale primarily within the Medicaid population rather than Medicare beneficiaries. This payer mix implies business reliance on state Medicaid contracts or ordering patterns rather than fee-for-service Medicare volume.
Revenue concentration is high for both payers but especially for Medicaid: the top three Medicare codes account for 78.3% of the provider's Medicare revenue, and the top three Medicaid codes account for 93.7% of its Medicaid revenue. This indicates that a small set of drug-testing services drive nearly all reimbursed activity, making the organization highly specialized and vulnerable to changes in reimbursement or ordering patterns for those specific codes.
On Medicare, the provider records modest national standing for its leading codes: its G0480 volume ranks #70 of 1590 providers nationally (96th percentile) and 80307 ranks #144 of 4760 (97th percentile), which the source describes as typical, unremarkable volume for those codes at this provider’s scale. These percentiles indicate solid national presence for these test types but not market dominance; Medicare activity appears concentrated but within expected ranges for toxicology labs.
On Medicaid, the provider is a state-level outlier and appears dominant for core drug-testing codes: it ranks #1 in-state for G0480, 80307 and G0481 (each at the 100th percentile) and is described as an "extreme outlier, far above typical state volume for this code." That combination of being top-ranked across multiple high-revenue codes positions NEPENTHE as a major Medicaid toxicology testing vendor in Oregon.
The provider’s Medicaid billing volumes for individual codes are unusually large in absolute claim counts: examples include 115.7K claims for G0480 and 144K claims for 80307 in Medicaid, which the dataset flags as extreme statewide outlier volumes. Those volumes, paired with the $62 and $38 average paid/claim on those codes respectively, make these codes the primary revenue engines behind the provider’s $16.6M Medicaid total.
Service-line detail shows a tiered testing workflow: high counts for 80307 (presumptive instrumented screening) combined with substantial G0480/G0481/G0482 definitive testing indicates a common practice pattern where broad automated screens are followed by confirmatory definitive testing for positive or medically indicated results. This suggests operational capacity for both high-throughput screening and more resource-intensive confirmatory assays.
The practice has sustained presence in the national registry: NPI enumeration occurred on 2013-06-04 (~13 years ago), indicating a decade-plus of operation under this NPI which supports the observed high Medicaid volumes as an established state vendor rather than a recent entrant. Continued high-ranking Medicaid activity combined with long tenure suggests entrenched referral or contract relationships within Oregon.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
5 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1,410 | $110 | $158.1K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 1,630 | $60 | $99.2K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 370 | $200 | $72.9K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 470 | $150 | $71.5K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 80 | $240 | $20.1K |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 5 CPT/HCPCS codes.
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
12 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 115,700 | $60 | $7.2M |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 143,980 | $40 | $5.5M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 35,050 | $80 | $2.9M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 8,160 | $100 | $824.1K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1,520 | $150 | $225.3K |
| 80324 | The lab analyst measures the amount of or detects the presence of one or two amphetamines, a central nervous system stimulant in a patient specimen. | 70 | $0 | $0 |
| 80346 | The lab analyst measures the amount of or detects the presence of one to twelve benzodiazepines, which are tranquilizers, in a patient specimen. | 40 | $0 | $0 |
| 80348 | The lab analyst measures the amount of or detects the presence of buprenorphine in a patient specimen. Buprenorphine is a drug used to treat opioid addiction, to control acute pain in individuals who… | 60 | $0 | $0 |
| 80356 | The lab analyst measures the amount of or detects the presence of heroin metabolite in the patient specimen. | 70 | $0 | $0 |
| 80361 | The lab analyst measures the amount of or detects the presence of one or more opiates, narcotic analgesics that depress the central nervous system, in the specimen. | 80 | $0 | $0 |
Showing 1–10 of 12
How this provider's Medicaid billing volume and revenue compare to other Oregon providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Oregon median
12 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1 | 60 | 420 | $60 | $405.1K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1 | 10 | 290 | $90 | $379.1K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1 | 10 | 3,880 | $90 | $364.5K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 1 | 80 | 1,210 | $40 | $294.3K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 4 | 10 | 1,520 | $100 | $218.3K |
| 80362 | The lab analyst measures the amount of or detects the presence of one or two opioids and opiate analogs, narcotic analgesics that depress the central nervous system, in the specimen. | 2 | 10 | 240 | $40 | $9.8K |
| 80365 | The lab analyst measures the amount of or detects the presence of oxycodone, a synthetic opioid pain medication, in a patient specimen. | 5 | 10 | 190 | $20 | $5.1K |
| 80361 | The lab analyst measures the amount of or detects the presence of one or more opiates, narcotic analgesics that depress the central nervous system, in the specimen. | 4 | 10 | 200 | $20 | $3.9K |
| 80324 | The lab analyst measures the amount of or detects the presence of one or two amphetamines, a central nervous system stimulant in a patient specimen. | 3 | 10 | 180 | $20 | $3.9K |
| 80346 | The lab analyst measures the amount of or detects the presence of one to twelve benzodiazepines, which are tranquilizers, in a patient specimen. | 4 | 10 | 190 | $20 | $3.7K |
Showing 1–10 of 12
Other providers in the same ZIP code as Nepenthe Laboratory Services LLC, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Willamette Family, Inc | OR | Substance Abuse Rehabilitation Facility | $0 | $66M |
| Icco, LLC | OR | Urgent Care Clinic/Center | $0 | $11.3M |
| City Of Eugene | OR | Land Ambulance | $1.2M | $9.9M |
| City Of Springfield | OR | Land Ambulance | $575.8K | $5M |
| Eugene Kids' Dentist, LLC | OR | Pediatric Dentistry | $0 | $4.2M |
| Advanced Health Chiropractic PC | OR | Chiropractor | $0 | $3.8M |
| Bhs Eugene Inc. | OR | Long Term Care Pharmacy | $40.1K | $2.3M |
| Mid Valley Ambulance Service Inc. | OR | Land Ambulance | $298.4K | $2M |
| Centennial Medical Equipment Inc | OR | Durable Medical Equipment & Medical Supplies | $0 | $2M |
| Timothy Richardson | OR | Pediatric Dentistry | $0 | $1.5M |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.